Fed Circuit cancels skin cancer detection patent

The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

The quantum advantage: IP considerations for the next generation of life sciences innovation

27 January 2026 As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper

Americas

Fed Circ overturns PTAB decision in $83.4m DNA case

26 January 2026 The court found the board applied the wrong legal standard when evaluating Guardant Health’s obviousness challenge to a University of Washington DNA sequencing patent.

Americas

AI is transforming top 100 innovators, shows index

23 January 2026 Just one pharma company is recognised in a report that lists the most world's most inventive countries and companies.